Aptimmune Biologics
Champaign, US · Illinois corporation · 6 known investors
Aptimmune develops vaccines for swine health, partnering with vaccine development and swine health consulting companies to speed product development, testing and manufacturing. It serves the swine veterinary and animal health industry.
AgTechBiotechHealthtech
Founders & leadership
AG
Aaron GilbertieCEO
FZ
Federico ZuckermannNamed on SEC filing
Board
RE
Robert EasterBoard director
PO
Paul OlivoBoard director
GD
Gary DurackBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$4.6M disclosed across 2 rounds · 2015–2017
▶$2.2MraisedJul 2017 · 3 investors · BiotechnologyRule 506(b)
▶$2.2MraisedJul 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul OlivoDirector
- Aaron GilbertieExecutive Officer, Director
- Gary DurackDirector
- Robert EasterDirector
- Federico ZuckermannExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $2.2M
- Minimum investment
- $80K
- Proceeds to insiders
- $400K
- First sale
- Jun 2017
- Incorporated
- Corporation, Illinois
- Federal exemptions
- 06b
▶$2.4MraisedMar 2016 · 8 investors · BiotechnologyRule 506(b)
▶$2.4MraisedMar 2016 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert EasterDirector
- Paul OlivoDirector
- Aaron GilbertieExecutive Officer, Director
- Gary DurackDirector
- Federico ZuckermannExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $2.4M
- Minimum investment
- $1
- Proceeds to insiders
- $432K
- First sale
- Jun 2015
- Incorporated
- Corporation, Illinois
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 9
by search overlap
Primmune Therapeutics8 shared keywordsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Adaptimmune8 shared keywordsAdaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
Georgiamune6 shared keywordsGeorgiamune is a biotechnology company developing immunotherapies and cancer vaccines, working across immuno-oncology modalities including vaccines, antibodies, small molecules, and CAR-T cells. Founded by immunotherapy pioneer Dr. Samir N. Khleif, the company focuses on translational immune therapies for cancer and immune-related diseases.
Maxymune Therapeutics5 shared keywordsMaxymune is a pharmaceutical company developing treatments for immunological diseases, including a small-molecule LAT1 inhibitor program targeting overactive T-cells in autoimmune conditions and an improved formulation of mycophenolic acid intended to reduce gastrointestinal side effects. Its work spans drug discovery and formulation of immunosuppressive therapies for patients with immunological disorders.
Thymmune5 shared keywordsThymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
Evommune5 shared keywordsEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
Syncromune5 shared keywordsSyncromune is developing SYNC-T, an in situ combination immunotherapy platform delivered directly into a target tumor to prompt the immune system to recognize and destroy cancer throughout the body. Its lead investigational therapy SV-102 is being evaluated in the LEGION-100 Phase 2 trial for metastatic castration-resistant prostate cancer.</parameter>
<parameter name="founders">[]
Immunome4 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
NexImmune4 shared keywordsNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
Companies competing with Aptimmune Biologics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of Agriculture (USDA) | Phase II | 2017 | $600K |
| Department of Agriculture (USDA) | Phase I | 2015 | $99.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Aptimmune Biologics do?
- Aptimmune develops vaccines for swine health, partnering with vaccine development and swine health consulting companies to speed product development, testing and manufacturing. It serves the swine veterinary and animal health industry.
- Who are Aptimmune Biologics's investors?
- Aptimmune Biologics's investors include Missouri Technology Corporation, Arsenal, Cultivation Capital, The Yield Lab, Illinois Ventures, The Yield Lab Asia Pacific.
- How much funding has Aptimmune Biologics raised?
- Aptimmune Biologics has disclosed $4.6M raised across 2 rounds.
- Where is Aptimmune Biologics headquartered?
- Aptimmune Biologics is headquartered in Champaign, US.